- Previous Close
1.5700 - Open
1.5950 - Bid 1.5750 x --
- Ask 1.6700 x --
- Day's Range
1.5750 - 1.6000 - 52 Week Range
1.3500 - 2.2600 - Volume
12,217 - Avg. Volume
40,414 - Market Cap (intraday)
176.708M - Beta (5Y Monthly) 0.70
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1000 - Earnings Date Aug 26, 2024
- Forward Dividend & Yield 0.01 (0.74%)
- Ex-Dividend Date Sep 1, 2023
- 1y Target Est
3.10
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. The company operates through Technegas and Molecular Imaging segments. The Technegas segment offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. This segment also distributes products to the diagnostic imaging sector. The Molecular Imaging segment provides radiopharmaceuticals that are used by physicians in the detection of cancer, neurological disorders, and cardiac diseases. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is headquartered in Kingsgrove, Australia.
www.cyclopharm.comRecent News: CYC.AX
View More
Performance Overview: CYC.AX
Trailing total returns as of 10/21/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CYC.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CYC.AX
View MoreValuation Measures
Market Cap
176.71M
Enterprise Value
154.72M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.47
Price/Book (mrq)
3.72
Enterprise Value/Revenue
6.65
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-38.72%
Return on Assets (ttm)
-15.37%
Return on Equity (ttm)
-22.59%
Revenue (ttm)
24.06M
Net Income Avi to Common (ttm)
-9.32M
Diluted EPS (ttm)
-0.1000
Balance Sheet and Cash Flow
Total Cash (mrq)
28.89M
Total Debt/Equity (mrq)
11.72%
Levered Free Cash Flow (ttm)
-6.99M
Research Analysis: CYC.AX
View MoreCompany Insights: CYC.AX
CYC.AX does not have Company Insights